Chronic Myeloid Leukemia News and Research

RSS
Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.
Anti-emetic drug offers a promising approach to treat chronic myeloid leukemia

Anti-emetic drug offers a promising approach to treat chronic myeloid leukemia

Drug intervention may prevent heart damage caused by chemotherapy

Drug intervention may prevent heart damage caused by chemotherapy

Researchers investigate protein phosphatase to identify new treatments for cancer, other diseases

Researchers investigate protein phosphatase to identify new treatments for cancer, other diseases

IU research findings could prevent common complication of blood stem cell transplantation in leukemia

IU research findings could prevent common complication of blood stem cell transplantation in leukemia

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Researchers find a new therapeutic approach to combat leukemia

Researchers find a new therapeutic approach to combat leukemia

Exponential rise in COVID-19 hospitalization risk with age due to waning T cell immunity

Exponential rise in COVID-19 hospitalization risk with age due to waning T cell immunity

Research reveals the molecular landscape of myelodysplastic/myeloproliferative neoplasms

Research reveals the molecular landscape of myelodysplastic/myeloproliferative neoplasms

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Using genome-wide CRISPR technology to identify leukemia's weakness

Using genome-wide CRISPR technology to identify leukemia's weakness

OGT delivers translocation and partial tandem duplication detection with updates to SureSeq NGS portfolio

OGT delivers translocation and partial tandem duplication detection with updates to SureSeq NGS portfolio

Report highlights steady 26-year decline in overall cancer mortality

Report highlights steady 26-year decline in overall cancer mortality

Cancer drug shows promise in battling Parkinson’s disease

Cancer drug shows promise in battling Parkinson’s disease

Study shows nilotinib drug is safe and well tolerated in patients with Parkinson's disease

Study shows nilotinib drug is safe and well tolerated in patients with Parkinson's disease

Scientists highlight the benefits of Droplet Digital PCR technology at the 2019 ASH meeting

Scientists highlight the benefits of Droplet Digital PCR technology at the 2019 ASH meeting

Finding ways to stop cancer at its roots

Finding ways to stop cancer at its roots

Leukemia drug appears to be effective in treating deadly pediatric brain tumor

Leukemia drug appears to be effective in treating deadly pediatric brain tumor

Leukemia is not just one disease

Leukemia is not just one disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.